Patent · US Active

Biomarkers for treatment of neoplastic disorders using androgen-targeted therapies

US9387216B2 · kind B2 · utility

6Cited by

126References

30Claims

0Family size

Assignees

Tokai Pharmaceuticals, Inc. · US
University of Washington · US
UNIVERSITY OF MARYLAND, BALTIMORE · US

Inventors

Vincent C. O. Njar · Glen Burnie, US
Amina Zoubeidi · West Vancouver, CA
Karen Ferrante · East Greenwich, US
Eva Corey · Seattle, US
Douglas B. Jacoby · Wellesley, US

Key dates

Filing date	Jul 6, 2015
Grant date	Jul 12, 2016
Priority date	—
Expiry date	Jul 6, 2035

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12Q2600/158
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Described herein are methods and compositions for the treatment of prostate cancer in a subject in need thereof. The prostate cancer may be a castration resistant and an androgen receptor antagonist-resistant prostate cancer. The methods may comprise administering to the subject a CYP17-lyase inhibitor of Formula II.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.